16723: Worth Less Shows More Bias.

 

MM+M spotlighted the latest patronizing propaganda from FCB Health New York’s Trial for #ClinicalEquality campaign, an initiative designed to expose the racial and ethnic bias in clinical trials.

 

As pointed out in a previous post, the revelation that people of color receive unequal treatment from the US healthcare system is hardly surprising—in fact, it’s common knowledge—and arguably offensive coming from a White advertising agency likely fishing for awards versus advocating for justice.

 

To compound the cultural cluelessness, the new advertisements feature AI-rendered images of Black patients. So, in addition to using an executional method that has displayed bias, FCB Health deprived talent of color from the opportunity to receive payment and recognition for appearing in a national campaign. Surely the hardest-working man in Black advertising could have been tapped.

 

In short, the advertising stunt presented parallel prejudice: unequal representation in clinical trials and underrepresentation in commercial concepts.

 

AI portraits highlight the lack of diversity in clinical research

 

The Worth Less campaign is the latest initiative from FCB Health New York’s Trial for #ClinicalEquality.

 

By John Newton

 

The initial inspiration for the Trial for #ClinicalEquality, a longstanding initiative from IPG Health’s FCB Health New York, struck seven years ago. In the course of looking at clinical trial data intended to support a creative campaign, the agency realized they didn’t reflect the people it hoped to reach.

 

“It wasn’t an isolated incident,” noted IPG Health chief medical officer Dr. Sommer Bazuro. “We needed data to reflect, first, the racial groups within the overall population and, second, the disease incidence and mortality rates for that specific population.”

 

Since then, the Trial for #ClinicalEquality has highlighted the costs of a lack of diversity in clinical trials — to both individuals and society broadly. One study, for instance, found that there were no Native American participants in diabetes clinical trials registered on ClinicalTrials.gov from March 2000 to March 2020.

 

The lack of diversity undermines public trust in scientific research and results in lower-quality data. Also, financial costs accrue due to health disparities that could be reduced with trials that are more reflective of the populations impacted by certain diseases.

 

Worth Less, the initiative’s latest campaign, features 15 portrait-like images that were created using generative AI licensed from Adobe Stock. Its overarching goal is to call attention to the ethnic minority groups impacted by clinical inequality.

 

The campaign’s name is designed to be read two ways, asking whether the lives of patients of color are worthless as well as whether they are worth less than other patients’ lives. The photo captions highlight the wider implications of failing to include patients from certain demographic groups in clinical trials with statistics: “1% of clinical trial participants are Asian, yet chronic hepatitis B affects them the most” and “2% of patients in dementia clinical trials are Black, yet they experience this disease at the second highest rate.”

 

Bazuro believes that many patients and physicians simply assume that clinical trials are reflective of the communities impacted by specific conditions or diseases.

 

“Most people, even those who have been in healthcare for years, don’t realize that it’s not happening,” she says. “They don’t know that when their physicians talk to them about medicines, that they cannot be 100% confident that someone who has their particular background was included. That’s something that troubles physicians.”

 

The Worth Less messaging centers on the financial implications of non-diverse trials. Bazuro explained that the perceived greater expense of diverse clinical trials is a common concern — but that the societal costs of lower-quality data, mistrust of the healthcare system and disparate outcomes need to be considered as well.

 

“We know how the world works: If you can’t fund it, it’s not getting done,” added FCB Health New York chief creative officer Kathleen Nanda. “That’s just the reality of business and, very often, health is a business.”

 

The campaign website includes a host of statistics, including one explaining that, from 2003 to 2006, medical expenses could have been reduced by $230 billion if inequalities faced by patients of color had been eliminated.

 

“We want people to understand the urgency of data equality and clinical equality and to take action,” Nanda said. “We want this problem to be seen and to be fixed by a bunch of brilliant different minds. It’s not just what we are doing; it’s what our community is doing that we’re really, really excited about.”